Sudoscan® reclassifies cardiovascular risk in patients with type 2 diabetes mellitus according to the ESC 2023

Abstract

Objectives: The objective of this study is to determine if the detection of DAN through Sudoscan® can reclassify cardiovascular risk in patients with T2DM according to the European Society of Cardiology guidelines 2023 (ESC 2023) compared to other risk scales. Methods: A retrospective cross-sectional analytical study was conducted on 161 patients with T2DM who had undergone Sudoscan® in a Northern Mexico Hospital between December 2022 and July 2023. We compared the cardiovascular risk with SCORE-2, SMART, ADVANCE, ASCVD plus, and Globo Risk scales. Results: Estimated cardiovascular risk according to the ESC 2023 without consideration of DAN was low for 91 (57%), moderate for 53 (33%), high for 11 (7%) and very high for 22 (3%) of patients. While inclusion of DAN resulted in low risk in 81 (51%), moderate in 46 (28%9, high in 9(5%) and very high risk for 25 ((16%), p = 0.004). The majority of patients were classified as low or moderate risk using other scales such as ASCVD plus, SCORE-2, Globo Risk, ADVANCE, and SMART. Conclusions: Sudoscan® enhances cardiovascular risk assessment in T2DM by accurately diagnosing microvascular complications, ensuring comprehensive patient evaluation.